Santa Barbara, CA—Miravant Medical Technologies will conduct phase III clinical trials for rostaporfin (PHOTREX) at 50 investigational sites in central and eastern Europe and the United Kingdom to evaluate a range of patients with wet age-related macular degeneration.
Santa Barbara, CA-Miravant Medical Technologies will conduct phase III clinical trials for rostaporfin (PHOTREX) at 50 investigational sites in central and eastern Europe and the United Kingdom to evaluate a range of patients with wet age-related macular degeneration.
The FDA will review the randomized, placebo-controlled trial under a Special Protocol Assessment.
The company plans to conduct a primary efficacy endpoint analysis at 12 months of about 600 patients.
